Please login to the form below

Not currently logged in
Email:
Password:

drug rebates

This page shows the latest drug rebates news and features for those working in and with pharma, biotech and healthcare.

Trump budget targets rebates, out-of-pocket costs

Trump budget targets rebates, out-of-pocket costs

The budget proposes removing the cap on Medicaid manufacturer drug rebates “to ensure rebates reflect all price increases for a drug,” and would also prevent manufacturers from using authorised generics to ... The budget would fundamentally upset the

Latest news

  • Fireworks likely at Senate drug pricing hearing today Fireworks likely at Senate drug pricing hearing today

    Wyden tweeted yesterday that drug companies have been getting away with “highway robbery” on insulin pricing. ... group of overseas markets, and banning drug rebates between pharma companies and PBMs.

  • CEOs agree to Congressional grilling on US drug prices CEOs agree to Congressional grilling on US drug prices

    The President is calling for greater more drug pricing transparency, and HHS Secretary Alex Azar recently announced plans to ban drug rebates between pharma and PBMs, though this move would hit ... It is just one of several bills aimed at reduce or

  • End to middlemen rebates a major shift in US drug pricing End to middlemen rebates a major shift in US drug pricing

    The HHS said: “The proposal would also address the most significant incentive drug manufacturers cite in raising their list prices every year, the pressure to provide larger and larger rebates. ... There are many other proposals being put forward in

  • US insurers can peg access to ICER value reviews US insurers can peg access to ICER value reviews

    drug prices by pocketing rebates and not passing on savings to customers. ... It insists however this will not be a barrier to drug discovery – as is often cited by drugmakers – as companies currently “spend more on marketing that discovery”.

  • Pfizer CEO reckons rebates will disappear, and that’s a positive Pfizer CEO reckons rebates will disappear, and that’s a positive

    Abandoning rebates could deliver a situation where drug prices fluctuate in line with healthcare inflation – and that shouldn’t affect Pfizer’s sales growth predictions, said Read. ... The move also has the support of FDA Commissioner Scott

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Market access in Europe: balancing access and affordability Market access in Europe: balancing access and affordability

    However, if sales in that period exceed 250m, companies will be liable to pay rebates. ... In response to the pharmaceutical industry's concerns about international reference pricing, details of drug rebates will, in future, be available only to

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics